Hengrui medicine, a new diabetes drug, is expected to be put into production by the end of the year

Sun piaoyang, chairman of Hengrui pharmaceutical, said at a meeting organized by securities companies that the company's new diabetes drug regletin is expected to declare production by the end of this year "Now the third phase of clinical treatment has been put into the group After observing the clinical data for another six months, we will apply for production at the end of this year." Sun also pointed out that the company's new anti-tumor drugs apatinib and long-term Shengbai 9 biological drugs long-term G-CSF are expected to be approved for market this year According to the public information, regolitine is a class 1.1 new drug independently developed by Hengrui medicine, which is an oral blood glucose regulator Guangfa Securities pointed out that the global sales of siggliptin, the first of its kind, exceeded US $4 billion in 2012, with a growth rate of more than 20% The domestic market is just in its infancy, with three of the original R & D statins imported and two of them applied for import Among the domestic research of statins, Hengrui pharmaceutical is about two years ahead of its rivals GF Securities expects regletin to be listed in 2015, with a long-term sales volume expected to reach 2 billion yuan Hengrui pharmaceutical was mainly engaged in the first generic drugs before, and in recent years, the company is gradually transforming to innovative drugs The company has many innovative drugs in the fields of cardio cerebrovascular, tumor, diabetes and immunity